-
Mc-Val-Cit-PABC-PNP: ADC Workflow Guide
2026-09-01
Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker for constructing conjugates designed to release payloads after lysosomal protease cleavage. It is suited to controlled antibody-drug conjugate synthesis workflows using compatible organic solvent handling, but is not intended for aqueous formulation, diagnostic testing, or medical and therapeutic use.
-
Proteinase K in Fungal EV Assay Design
2026-09-01
Proteinase K can do more than support DNA workflows: it can serve as a controlled pre-analytical tool for testing protein accessibility in fungal extracellular vesicle assays. This article connects the enzyme’s biochemical behavior with recent Candida albicans research while defining practical controls, limitations, and optimization logic.
-
Biotin Azide Click-Labeling Workflows
2026-08-31
Biotin Azide converts terminal-alkyne-bearing DNA, proteins, and probe molecules into affinity-ready conjugates through selective CuAAC chemistry. This guide connects practical labeling, streptavidin capture, and controls to mechanistic questions inspired by the Fzd5–cholesterol–Wnt pathway.
-
Relative vs Fractional Viability in Cancer Drug Studies
2026-08-31
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that proliferation arrest and cell death are related but non-equivalent components of in vitro drug response. This framework improves interpretation of anticancer experiments by requiring researchers to consider response magnitude, composition, and timing rather than treating a single viability value as a complete pharmacological description.
-
CTCF, Centromeres, and Mitotic Fidelity
2026-08-30
The reference study uses rapid, inducible CTCF degradation to show that CTCF maintains centromere architecture, chromosome alignment, and accurate mitosis rather than simply recruiting CENP-E. Its findings distinguish a centromere-maintenance function from a primary chromosome-congression defect and provide a framework for interpreting mitotic perturbation experiments in cancer research.
-
I-BET-762: BET Inhibitor Workflows
2026-08-29
I-BET-762 is a selective BET inhibitor for connecting chromatin-dependent transcription with inflammatory signaling and ferroptosis. This practical guide presents a controlled cell-based workflow, assay choices, optimization checkpoints, and evidence-based ways to study ROS and FSP1 in cancer biology research.
-
Apigenin: From HDAC Assays to Network Biology
2026-08-28
Apigenin links HDAC-focused oncology assays with network-based neurobiology. This evidence-calibrated guide explains its molecular mechanism, assay design, handling requirements, and the limits of translating cross-domain findings.
-
LMP2A–mTORC1–GCNT3 Signaling in NPC
2026-08-28
A 2024 Virus Genes study identifies an LMP2A–mTORC1–GCNT3 axis in nasopharyngeal carcinoma (NPC), linking EBV latency to O-glycan regulation, epithelial–mesenchymal transition, migration, and proliferation. Its evidence supports GCNT3 and mTORC1 as mechanistically connected components of NPC biology, while also defining important limits for translating cell-culture findings into therapeutic strategies.
-
Thymoquinone Protects Against Doxorubicin Cardiotoxicity
2026-08-27
A 2025 study found that thymoquinone reduced doxorubicin-associated cardiac injury in mice, with evidence pointing to Nrf2/HO-1 activation, improved antioxidant capacity, and suppression of ferroptosis-related damage. The work strengthens the rationale for combining functional cardiac measurements with redox, iron-handling, and mitochondrial analyses in a doxorubicin cardiotoxicity model.
-
Pentoxifylline and TLR4 Hyperinflammation in Preterm Monocyt
2026-08-27
Schüller and colleagues used an in vitro whole-blood model to show that pentoxifylline suppresses LPS-induced inflammatory activation in monocytes from preterm and term infants, while revealing age-dependent effects on selected immune markers and IL-10 production. The study links these effects to reduced TLR4 expression and signaling, providing a mechanistic basis for evaluating pentoxifylline as an adjunctive strategy in neonatal sepsis research.
-
Q-VD(OMe)-OPh in Translational Apoptosis Research
2026-08-26
Q-VD(OMe)-OPh provides a mechanistic way to test whether apoptosis drives treatment response, resistance, or tissue injury. This thought-leadership guide connects pan-caspase inhibition with the 3-bromopyruvate–cetuximab resistance model and offers practical guidance for reproducible translational studies.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-08-26
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible research tool for examining TLR7/9 signaling and autophagy pathway modulation in autoimmune disease research. It is suited to short-term, water-based workflows but should not be selected for DMSO- or ethanol-based stocks or protocols requiring long-term storage of prepared solutions.
-
Ciclesonide: A Control for ERAD Research
2026-08-25
Ciclesonide is a lung-activated glucocorticoid prodrug with a distinct experimental value in respiratory biology. This article explains how its receptor pharmacology can serve as a mechanistic comparator when evaluating the newer ERAD-hijacking degradation platform described for transmembrane proteins.
-
Tivozanib (AV-951): A Better In Vitro Assay Strategy
2026-08-25
Tivozanib and AV-951 offer a precise model for studying VEGFR-driven angiogenic signaling. This article presents a time-resolved assay strategy that separates proliferative arrest from true cell death for more informative oncology experiments.
-
Ruxolitinib: From JAK Signaling to Assay Design
2026-08-24
Ruxolitinib (INCB018424) is a selective JAK1/2 inhibitor with strong utility in mechanistic hematology and myeloproliferative disorder research. This article explains how to connect biochemical inhibition, cellular phenotypes, and immune-assay design without overextending evidence from a distinct neonatal inflammation model.